IP Library Granted Patent US 8,465,759
Granted Patent B2
US 8,465,759 · App. 12/294,372 · Granted Jun 18, 2013

Process for the preparation of a hot-melt extruded laminate

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,465,759
App. No.
12/294,372
Granted
Jun 18, 2013
Kind
B2
Abstract

A process for the preparation of a bioadhesive laminate comprising a hot-melt extruded reservoir layer and a hot-melt extruded backing layer is provided. The reservoir layer comprises a thermoplastic bioadhesive composition containing an active agent. An active agent-containing thermoplastic bioadhesive hydrophilic composition is hot-melt coextruded with a hydrophobic composition to form at least a bi-layered laminate. The hydrophilic composition and the hydrophobic composition have at least one polymer in common. In addition, the melt flow index of the hydrophobic composition is within 50% of the melt flow index of the hydrophilic composition. As a result, the laminate has a uniform transverse cross-section and/or a uniform longitudinal cross-section throughout a major of the length of the laminate. Moreover, when the laminate is divided into unit doses of approximately the same size, they have a high degree of content uniformity with respect to the active agent(s) present therein.

Claims (21)

1. A bioadhesive bi-layered hot-melt extruded laminate comprising a hydrophilic bioadhesive reservoir layer and a hydrophobic backing layer, wherein

a) the bioadhesive reservoir layer comprises an active agent;

b) each of the bioadhesive reservoir layer and the backing layer comprises poly(ethylene) oxide (PEO); and

c) the backing layer comprises a hydrophilic polymer in a sufficiently low amount such that the backing layer is hydrophobic,

wherein the PEO in each layer is selected from the group consisting of PEO Grade 1, PEO Grade 2, PEO Grade 3, and a combination thereof, wherein: PEO Grade 1 is polyethylene oxide with (i) a solution viscosity in the range of 12-8800 mPa·s at 25° C. in a 5% solution, or (ii) an approximate molecular weight range from 100,000-600,000; PEO Grade 2 is polyethylene oxide with (i) a solution viscosity in the range of 8800 mPa·S at 25° C. in a 5% solution to 4000 mPa·s at 25° C. in a 2% solution, or (ii) an approximate molecular weight range from 900,000-2,000,000; and PEO Grade 3 is polyethylene oxide with (i) a solution viscosity in the range of 1650-15,000 mPa-s at 25° C. in a 1% solution, or (ii) an approximate molecular weight range from 4,000,000-8,000,000,

wherein the PEO in the bioadhesive reservoir layer comprises PEO Grade 1, PEO Grade 2, and PEO Grade 3.

2. The laminate of claim 1 , wherein the backing layer comprises two or more hydrophobic polymers.

3. The laminate of claim 1 , wherein the melt flow index of the reservoir layer is within 50% of the melt flow index of the backing layer.

4. The laminate of claim 1 , wherein the laminate comprises a controlled, sustained, slow, extended, or targeted release therapeutic composition.

5. The laminate of claim 1 , wherein the laminate comprises a dosage form adapted for transdermal, transmucosal, rectal, pulmonary, nasal, vaginal, ocular, or otic drug delivery, or as an implantable drug delivery device.

6. The laminate of claim 1 , wherein the active agent is selected from the group consisting of testosterone, oxybutynin, morphine, fentanyl, aspirin, lansoprazole, omeprazole, pantoprazole, rabeprazole and naltrexone.

7. The laminate of claim 1 , wherein each of the backing layer and the reservoir layer comprises at least 10% wt. of the PEO.

8. The laminate of claim 1 further comprising a release liner layer removably affixed to the reservoir layer.

9. The laminate of claim 1 , wherein the reservoir layer comprises 40 to 90% by wt. of the laminate.

10. The laminate of claim 1 , wherein the active agent is fentanyl.

11. The laminate of claim 1 , wherein the active agent is testosterone.

12. The laminate of claim 1 , wherein the bioadhesive reservoir layer further comprises an acidic component.

13. The laminate of claim 1 , wherein the PEO in the backing layer comprises two or more grades of PEO selected from the group consisting of PEO Grade 1, PEO Grade 2, and PEO Grade 3.

14. The laminate of claim 1 , wherein the reservoir layer comprises about 10% to about 70% wt. of the PEO.

15. A unit dose comprising a portion of a laminate according to claim 1 , wherein the reservoir layer has an average exposed surface area between 90 and 250 mm 2 .

16. The unit dose of claim 15 comprising a surface area to dose ratio of 5 to 35 mm 2 /mg active agent based upon the exposed surface of the reservoir layer.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Apr 26, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH HOLDINGS, LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO GENERIC HOLDINGS, INC. (FORMERLY KNOWN AS PAR PHARMACEUTICALS COMPANIES, INC.); ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067240/0001 →
RELEASE OF SECURITY INTEREST Recorded Apr 25, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR PHARMACEUTICAL COMPANIES, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067239/0542 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Apr 6, 2021
From: BIOSPECIFICS TECHNOLOGIES LLC; PAR PHARMACEUTICAL, INC.; AUXILIUM US HOLDINGS, LLC; ASTORA WOMEN'S HEALTH, LLC; ENDO PHARMACEUTICALS SOLUTIONS INC.; ENDO PHARMACEUTICALS, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 055846/0246 →
SECURITY INTEREST Recorded Jun 8, 2017
From: AUXILIUM US HOLDINGS, LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE
Reel/Frame 042742/0892 →
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2017
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: AUXILIUM US HOLDINGS, LLC; AUXILIUM INTERNATIONAL HOLDINGS, LLC; ACTIENT PHARMACEUTICALS LLC; SLATE PHARMACEUTICALS, LLC; TIMM MEDICAL HOLDINGS, LLC; ACTIENT THERAPEUTICS LLC; 70 MAPLE AVENUE, LLC; AUXILIUM PHARMACEUTICALS, LLC
Reel/Frame 042172/0421 →